Browse diseases

…nit inhibitor, is highly efficacious in participants (pts) with Crohn’s disease (CD). Phase 3 studies (GALAXI 2, GALAXI 3, and GRAVITI) showed …

…clonal antibody, in patients with moderately to severely active Crohn’s disease (CD). We present results from patients randomised to MIRI in th…

…e similarly effective in pts with moderately to severely active CD across predefined subgroups of disease location and baseline cl…

…rations and clinical and biochemical remission in patients with Crohn’s disease (CD) receiving maintenance therapy, analysing intravenous and s…

… in CD (p=0.027).Conclusions This study reveals an accelerating pIBD burden in a UAE centre, with CD predominance, complex phenotype…

… and ustekinumab (UST) in patients with Crohn’s disease (CD) or Ulcerative colitis (UC), and to assess the acceptance of the pharmaceutical recomm…

…lation is not performedAbstract 35 Figure 2Patient outcome. AF, atrial fibrillation; CRT, cardiac resynchronisation therapy; EF, ejection fraction;…

…Coeliac disease (CD) is an autoimmune condition, and its management is strict a…

… support the psychosocial wellbeing of young people living with Coeliac Disease and their families. Further evaluation with larger and more div…

…Background The pathogenesis of Crohn’s disease (CD) is closely associated with genetic factors and an imbalanc…

…uding 18 euthyroid, 9 hypothyroid, and 3 hyperthyroid patients. Type 1 diabetes occurred in 26.8% (n=11), and one patient had autoimmune hypoph…

…or risankizumab (RZB) in patients (pts) with moderate to severe Crohn’s disease (CD) and prior anti-TNF failure. Here, we evaluated the durabil…